IPP Bureau
Pfizer and Beam enter research collaboration for In Vivo base editing programme
By IPP Bureau - January 11, 2022
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Takeda to acquire Adaptate Biotherapeutics
By IPP Bureau - January 11, 2022
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Immune Biosolutions lead immunotherapy product neutralises Covid-19
By IPP Bureau - January 11, 2022
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Prof. Jason Kovacic bags Agilent Thought Leader award
By IPP Bureau - January 11, 2022
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
Molnupiravir best option to treat Covid-19 now: Experts
By IPP Bureau - January 11, 2022
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Intuitive India launches Intuitive Telepresence for remote surgical case observation
By IPP Bureau - January 11, 2022
Intuitive Telepresence (ITP), facilitates remote learning, and encourages interaction and collaboration between surgeons without the need to travel
Roche introduces cobas infinity edge
By IPP Bureau - January 11, 2022
Cobas infinity edge is designed as an open platform, allowing healthcare professionals to easily access and adopt third-party innovators’ new digital tools and medically-relevant applications via the Roche digital marketplace
Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets
By IPP Bureau - January 11, 2022
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
Algorithmic Biologics receives seed funding from Axilor Lab
By IPP Bureau - January 11, 2022
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
Mylab’s CoviSelf can detect Omicron: Study
By IPP Bureau - January 10, 2022
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Odisha is the first state to place order for OmiSure to detect Omicron
By IPP Bureau - January 10, 2022
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
Novartis and Molecular Partners report positive data for anti-viral Covid therapy
By IPP Bureau - January 10, 2022
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Alembic receives tentative U.S.FDA approval for dronedarone tablets
By IPP Bureau - January 10, 2022
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
Arch Pharmalabs signs agreement with Orchem Technologies to use SMB platform
By IPP Bureau - January 10, 2022
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report
By IPP Bureau - January 10, 2022
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
